Humana Inc vs Kyndryl Holdings Inc — how do they compare? Humana Inc trades at $442.01 (market cap $47.61B), while Kyndryl Holdings Inc trades at $11.86 (market cap $2.49B). The key difference: Humana Inc is far larger — about 19.1× Kyndryl Holdings Inc's market cap, and Humana Inc pays a 0.89% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Kyndryl Holdings Inc for 36 Days on average.
| HUM | KD | |
|---|---|---|
Market Cap | $47.61B | $2.49B |
Volume | 1,827,332 | 4,191,904 |
Sector | Health | Technology |
52-Week High | $409.85 | $29.76 |
52-Week Low | $163.67 | $10.59 |
Typical Hold Time | 53 Days | 36 Days |
Enterprise Value | $54.97B | $5.32B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Kyndryl Holdings (KD) trades at $11.45, down 0.26% on the day, with technical indicators showing bearish momentum. The company reported mixed quarterly results, missing Q4 2025 and Q1 2026 EPS estimates but beating in Q2 2026. Recent financials show improved profitability with 2025 net income of $252 million, though revenue has declined from $18.3B in 2022 to $15.1B in 2025. Analyst sentiment is cautious with a consensus 'Hold' rating and $14.67 price target, while institutional activity includes recent purchases by Virginia Retirement Systems.
KD presents a turnaround story with improving profitability but faces revenue headwinds and competitive pressures. The stock trades at reasonable valuation multiples (P/E 30.95, P/S 0.18) with positive cash flow generation. Key risks include ongoing revenue declines and high debt levels, while opportunities exist in AI initiatives and government contracts. The current technical weakness may present entry points for patient investors betting on management's execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →